Acute immunosuppression and syngeneic bone marrow transplantation in ocular autoimmunity abort disease, but do not result in induction of long-term protection.
Acute immunosuppression induced by total body irradiation (TBI) or cyclophosphamide (Cy) treatment, followed by syngeneic bone marrow transplantation (SBMT), was reported to be effective in inducing long-term tolerance in some autoimmune disease models. We examined the efficacy of this approach in the mouse model of experimental autoimmune uveoretinitis (EAU). Development of EAU induced by the interphotoreceptor retinoid binding protein (IRBP) was abolished almost completely by either TBI or Cy treatment, followed by SBMT, instituted one week after priming. In parallel, IRBP-specific delayed-type hypersensitivity (DTH) responses and lymph node cell proliferation were strongly suppressed or abolished. However, when these IRBP-immunized, lymphoablated and BM reconstituted mice were rechallenged with the immunizing antigen seven weeks after the primary immunization, they were not protected from developing disease, despite the fact that DTH and lymph node cell proliferation to the antigen were suppressed relative to controls. TBI treatment appeared somewhat more effective than Cy treatment as judged by its more profound effect on immunological responses. These results demonstrate the ability of acute immunosuppression followed by reconstitution of the immune system to inhibit the development of EAU, although long-term protection from disease was not achieved.
Savion
S
S
Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, USA. shoshans@plato.tau.ac.il
Silver
P B
PB
Chan
C C
CC
Caspi
R R
RR
D000818:Animals; D001324:Autoantigens / Q000494:pharmacology; D001327:Autoimmune Diseases / Q000139:chemically induced / Q000473:pathology / Q000628:therapy*; D015551:Autoimmunity / Q000276:immunology*; D001853:Bone Marrow / Q000187:drug effects / Q000276:immunology / Q000528:radiation effects; D016026:Bone Marrow Transplantation / Q000276:immunology*; D003520:Cyclophosphamide / Q000494:pharmacology; D005136:Eye Proteins / Q000494:pharmacology; D005260:Female; D006968:Hypersensitivity, Delayed / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control; D007108:Immune Tolerance / Q000276:immunology; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000494:pharmacology; D008198:Lymph Nodes / Q000276:immunology; D008213:Lymphocyte Activation / Q000276:immunology; D051379:Mice; D012173:Retinitis / Q000139:chemically induced / Q000473:pathology / Q000628:therapy*; D012177:Retinol-Binding Proteins / Q000494:pharmacology; D014185:Transplantation, Isogeneic; D014605:Uveitis / Q000139:chemically induced / Q000473:pathology / Q000628:therapy*; D014916:Whole-Body Irradiation; D000099214:Retinol-Binding Proteins, Interstitial
D001324:Autoantigens; D003520:Cyclophosphamide; D005136:Eye Proteins; D007166:Immunosuppressive Agents; D012177:Retinol-Binding Proteins; D000099214:Retinol-Binding Proteins, Interstitial